JP2024516164A5 - - Google Patents

Info

Publication number
JP2024516164A5
JP2024516164A5 JP2023564557A JP2023564557A JP2024516164A5 JP 2024516164 A5 JP2024516164 A5 JP 2024516164A5 JP 2023564557 A JP2023564557 A JP 2023564557A JP 2023564557 A JP2023564557 A JP 2023564557A JP 2024516164 A5 JP2024516164 A5 JP 2024516164A5
Authority
JP
Japan
Prior art keywords
formula
substituted
independently
composition according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026001 external-priority patent/WO2022226344A1/en
Publication of JP2024516164A publication Critical patent/JP2024516164A/ja
Publication of JP2024516164A5 publication Critical patent/JP2024516164A5/ja
Pending legal-status Critical Current

Links

JP2023564557A 2021-04-22 2022-04-22 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子 Pending JP2024516164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178453P 2021-04-22 2021-04-22
US63/178,453 2021-04-22
PCT/US2022/026001 WO2022226344A1 (en) 2021-04-22 2022-04-22 All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo

Publications (2)

Publication Number Publication Date
JP2024516164A JP2024516164A (ja) 2024-04-12
JP2024516164A5 true JP2024516164A5 (cg-RX-API-DMAC7.html) 2025-04-23

Family

ID=83722696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564557A Pending JP2024516164A (ja) 2021-04-22 2022-04-22 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子

Country Status (8)

Country Link
US (1) US20240207442A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326886A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516164A (cg-RX-API-DMAC7.html)
CN (1) CN117500933A (cg-RX-API-DMAC7.html)
AU (1) AU2022262422A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215509A1 (cg-RX-API-DMAC7.html)
IL (1) IL307874A (cg-RX-API-DMAC7.html)
WO (1) WO2022226344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102764250B1 (ko) * 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
WO2024006960A1 (en) * 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
CN120754284B (zh) * 2025-07-30 2026-05-12 中国医学科学院基础医学研究所 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
EP0637965B1 (en) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CA2763819A1 (en) 2009-06-02 2010-12-09 Nian WU Pure peg-lipid conjugates
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
RU2014104090A (ru) * 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
KR102764250B1 (ko) * 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
WO2018087753A1 (en) * 2016-11-08 2018-05-17 Technology Innovation Momentum Fund (Israel) Limited Partnership Cationic lipids for nucleic acid delivery and preparation thereof
EP3781677A4 (en) * 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
US12357580B2 (en) * 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2606038B (en) * 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CA3121191A1 (en) * 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
US20220154222A1 (en) * 2019-03-14 2022-05-19 The Broad Institute, Inc. Novel nucleic acid modifiers
US12365921B2 (en) * 2019-05-30 2025-07-22 National University Corporation Hokkaido University Lipid nanoparticle
WO2022204043A1 (en) * 2021-03-22 2022-09-29 The Board Of Regents Of The University Of Texas System Compositions and methods for targeted delivery to cells
MX2023011227A (es) * 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
KR20240024041A (ko) * 2021-03-23 2024-02-23 리코드 테라퓨틱스, 인크. 세포로의 표적화 전신 전달을 위한 조성물 및 방법
US20240261440A1 (en) * 2021-04-05 2024-08-08 The Board Of Regents Of The University Of Texas System Compositions, methods and uses for treating cystic fibrosis and related disorders
AU2022253004A1 (en) * 2021-04-05 2023-10-12 Recode Therapeutics, Inc. Compositions, methods and uses for treating cystic fibrosis and related disorders
US20250276089A1 (en) * 2022-05-03 2025-09-04 The Board Of Regents Of The University Of Texas System Co-delivery of inhibitory nucleic acids and genome editors for tumor therapy

Similar Documents

Publication Publication Date Title
JP7258773B2 (ja) α-1アンチトリプシン(AAT)RNAi剤、AAT RNAi剤を含む組成物、及び使用方法。
JP2022031692A5 (cg-RX-API-DMAC7.html)
TW202415389A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
AU2005238490B2 (en) Improved modulators of coagulation factors
TW202024324A (zh) 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法
JP2020534268A (ja) アンジオポエチン様3(ANGPTL3)の発現を阻害するためのRNAi剤および組成物、ならびに使用方法
JP2020503010A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2018537403A5 (cg-RX-API-DMAC7.html)
JP2020503009A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
KR20180128423A (ko) 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
JP2002524038A (ja) Vegf発現の抑制のための短鎖オリゴヌクレオチド
KR20020033744A (ko) 사람 eg5의 발현을 억제하는 올리고뉴클레오티드
TW202426645A (zh) 用於抑制DM1蛋白質激酶(DMPK)表現之RNAi藥劑、其組合物及使用方法
KR20250024813A (ko) 치료제를 cns 조직으로 전달하기 위한 지질 접합체
JP2024086876A (ja) アシアロ糖タンパク質受容体1の発現を阻害するためのRNAi剤および組成物
JP2025500547A5 (cg-RX-API-DMAC7.html)
JP2001523451A (ja) 白斑治療のためのテナシンアンチセンスオリゴヌクレオチド
JP2002523335A (ja) Vegf発現の抑制のためのアンチセンスオリゴヌクレオチド
IL283646B2 (en) Exon skipping oligomer conjugates for muscular dystrophy
US12503696B2 (en) RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use
PT1888748E (pt) Formação estável e seletiva de triplex e duplex do tipo hoogsteen utilizando ácidos nucléicos torcidos e intercalados (tina) e processo para a preparação de tina
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法
CN118878604B (zh) 磷酯骨架修饰的核苷酸及寡核苷酸
WO2026030215A1 (en) Lipid conjugates for the delivery of therapeutic agents
CN121752721A (zh) 用于多聚体RNAi剂缀合物的肝脏递送平台及其使用方法